FdaApplication
BLA 021106
Identifiers
- fda_app_no: BLA021106
Properties
| Property | Value |
|---|---|
| applicant_name | Pharmacia & Upjohn Company LLC |
| application_type | BLA |
| approval_date | 2003-03-25 |
Revenue by product
SOMAVERT
| Period | Revenue |
|---|---|
| Q4 2023 | $67.0M |
| Q3 2023 | $69.0M |
| Q2 2023 | $65.0M |
| Q1 2023 | $66.0M |
| Q4 2022 | $66.0M |
| Q3 2022 | $70.0M |
| Q2 2022 | $64.0M |
| Q1 2022 | $68.0M |
| Q4 2021 | $74.0M |
| Q3 2021 | $70.0M |
| Q2 2021 | $68.0M |
| Q1 2021 | $65.0M |
| Q4 2020 | $79.0M |
| Q3 2020 | $67.0M |
| Q2 2020 | $67.0M |
| Q1 2020 | $64.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (5)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| SOMAVERT | PEGVISOMANT | 25MG | For Injection |
| SOMAVERT | PEGVISOMANT | 15MG | For Injection |
| SOMAVERT | PEGVISOMANT | 30MG | For Injection |
| SOMAVERT | PEGVISOMANT | 10MG | For Injection |
| SOMAVERT | PEGVISOMANT | 20MG | For Injection |
5 products